

## CURRICULUM VITAE

**INVESTIGATOR NAME:** Alejandro Julio Pereyra  
**INVESTIGATOR NACIONALITY:** Argentine  
**LICENSE NUMBER:** 93608  
**STUDY LOCATION ADDRESS:** Centro de Investigaciones Médicas Mar del Plata  
Av. Colón 3083 1°, 4°, 5° y 7° piso, B7600FYK Mar del Plata, Bs As, Argentina.  
Tel. +54 223-4917628/ 4956654

**EDUCATION: List Colleges/ Universities attended with dates and degrees obtained**

1990-1999, Facultad de Ciencias Médicas de la Universidad de La Plata

**Degree:** Physician

**POSTGRADE: Speciality, dates, institution's name**

Specialist in Internal Medicine. 2009, Colegio de Médicos de Buenos Aires Distrito IX.

- Certificate of "Good Clinical Practice (GCP)" - Novartis. March 19<sup>th</sup>, 2014

-Training Certificated Of Good Clinical Practice (GCP). FEFYM. November 2016

-Training in Ethics of the research. Conducted by Dr. Ignacio Maglio. Aug 2017

Sep 2018- Course of Ethics and Good Clinical research Practice. Ministerio de Salud de la Nación. Duration 80 hs

-July 2019-Good Clinical Research Practices. Brookwood

-Aug 2022- Good Clinical Research Practices NIDA Clinical Trials Network

**PROFESSIONAL EXPERIENCE:**

**· Board certification/ Name of board:**

Specialist in Internal Medicine. 2009, Colegio de Médicos de Buenos Aires Distrito IX.

**· Previous appointments (List positions held, gives dates and institutions):**

2007 – 2010: OOSS DIBA's family doctor. Mar del Plata, Buenos Aires.

2006: Obra Social de Empleados de Maestranza's family doctor. Mar del Plata, Buenos Aires.

2005 – 2006: SEMIN's family doctor. Mar del Plata, Buenos Aires.

2005: OSUTHGRA's medical audit. Mar del Plata, Buenos Aires.

2004 – 2005: Emergency doctor on call, Clínica Pueyrredón. Mar del Plata, Buenos Aires.

2007-2011: OOSS: SUTERYH's Clinical doctor. Mar del Plata, Buenos Aires.

2004 – 2009: Obra Social de Choferes de Camiones's family doctor. Mar del Plata, Buenos Aires.

2003: Municipal Physician, with activity at the Alto Camet Health Center. Mar del Plata, Buenos Aires.

2002 – 2003: Resident in Chief of Integral General Medicine at the HIGA Oscar Alende. Mar del Plata, Buenos Aires.

2002: Teacher of the capacitation course on diabetes mellitus for health professionals. Mar del Plata, Buenos Aires.

1999 – 2002: Integral General Medicine Resident at the HIGA Oscar Alende, with activity at the Alto Camet Health Center and the Camet Station. Mar del Plata, Buenos Aires.

1997 – 1999: D lectureship of internal medicine's assistant, Hospital General San Martín, Universidad Nacional de la Plata. La Plata, Buenos Aires.

**· Present appointment:**

Since August 2015: Sub Director of Centro de Investigaciones Médicas Mar del Plata

Since 2014: Clinical Medicine, staff of Centro de Investigaciones Médicas Mar del Plata

Since 2014: Clinical Medicine, staff of Centro de Investigaciones Médicas, Clínica de Fracturas y Ortopedia. Mar del Plata

Since 2007: PAMI's family doctor. Mar del Plata, Buenos Aires.

Since 2004: Medical clinic private practice. "Centro Médico Mar del Plata". Mar del Plata, Buenos Aires.

**COURSES**

2013: High blood pressure refresher course with final assessment. 8° International Cardiology Congress, Federación Argentina de Cardiología. Buenos Aires.

2013: "Investigation management and clinical trial's monitoring", 130 hours course with final assessment. Instituto Universitario CEMIC. Buenos Aires

2012 – 2013: Ambulatory medicine course, 250 hs with final assessment. Hospital Italiano, Buenos Aires.

2010: "The medication use on the geronte", with final assessment. ASAMED. Buenos Aires.

2009: 2° International smoking treatment training course, with final assessment. Mar del Plata, Buenos Aires.

2008-2009: Capacitation postgrade distance course, 466 hs with final assessment, "Metabolic syndrome and cardiovascular risk". FEPREVA, Buenos Aires.

2009: Vº Medical clinic course: "Diagnosis and treatment advances". 205 hs with final assessment. Escuela Superior de Educación Médica del IX Distrito del Colegio de Médicos de la Provincia de Buenos Aires.  
2000 – 2001: General epidemiology course for professionals. 400 hs with final assessment. Instituto Nacional de Epidemiología "Dr. Juan H. Jara". Mar del Plata, Buenos Aires.  
2000: Primary attention cardiology intracongress course. XV General Medicine National Congress. Mar del Plata, Buenos Aires.  
2002: Cardiopulmonary resuscitation during childhood course. Hospital Materno Infantil, Mar del Plata, Buenos Aires.

#### **CONGRESS**

2013: II Internal medicine congress of the Atlantic Coast. Mar del Plata, Buenos Aires.  
2013: ESC's congress. Amsterdam, Holland.  
2012: XIV International Congress of internal medicine. Buenos Aires.  
2010: International symposium: "Hepatology diagnosis and treatment". Buenos Aires.  
2010: XIII International congress of internal medicine. Buenos Aires.  
2006: Hepatology international symposium "Hepatitis B and C in the immunocompetent and the HIV coinfection. Buenos Aires.  
2005: IV Argentinian Federation of general and family medicine. Mar del Plata, Buenos Aires.  
2005: XIII Hepatology Argentinian Congress. Buenos Aires.  
2005: Updating conference "Portal high blood pressure, its complications and hepatocarcinoma". Buenos Aires.  
2004: 1º High blood pressure and cardiovascular risk factors conference. Mar del Plata, Buenos Aires.  
2003: XVII General Medicine National Congress. El Bolsón, Rio Negro.  
2003: V General Medicine International Congress. El Bolsón, Rio Negro  
2003: XIII Health department congress. El Bolsón, Rio Negro.  
2003: X Argentinian high blood pressure congress, High Blood Pressure Argentinian Society. La Plata, Buenos Aires.  
2002: VI Buenos Aires' General medicine residence conference. Tandil, Buenos Aires.  
2002: XVII General medicine National congress. San Luis  
2002: IV General medicine international congress. San Luis  
2002: XII Health department congress. San Luis  
2001: V Buenos Aires' General medicine residence conference. Azul, Buenos Aires.  
2001: XVI General medicine National congress. Santa Fé  
2001: III International general medicine congress. Sanata Fé  
2001: XI Health department congress. Santa Fé.  
2000: XV General medicine National congress. Mar del Plata, Buenos Aires.  
2000: II General medicine International congress. Mar del Plata, Buenos Aires.  
2000: X Health department congress. Mar del Plata, Buenos Aires.  
1999: II Provincial residences conference. Mar del Plata, Buenos Aires.  
1999: II Primary attention and permanent health education in the VIII sanitary region conference. Mar del Plata, Buenos Aires.

#### **PROFESSIONAL EXPERIENCE IN CLINICAL INVESTIGATION**

**VESTRI** Phase III Asthma in children Since Dec-2014 -2016 Sub investigator  
**SUMMIT** Phase III COPD Since Jan-2015-2016. Sub investigator  
**EXSCEL** Phase III Diabetes 2 and CV valuation Since Jan-2015-2017. Sub investigator  
**CQVA** Phase III. Epoc. Since 2014-2016. Sub Investigator  
**EUCLID** Phase IIIb Peripheral vascular disease. Since 2014-2016. Sub Investigator  
**CANTOS** Phase III Acute myocardial infarction. Since 2014-2017 Sub Investigator  
**ODYSSEY** Phase IIIb. Acute coronary syndrome. Since 2014. Sub Investigator  
**DECLARE** Phase IIIb. Diabetes type II and cardiovascular risk. Since 2014. Sub Investigator  
**B12610007** Phase III. Diabetic nephropathy. Since 2014-2015. Sub Investigator  
**NN-95353626**. Phase IIIa. Diabetes type II and Metformina failure. Since 2014-2016. Sub Investigator  
**DIA4003**. Phase III. Diabetes II and cardiovascular risk.2014-2017 Sub Investigator  
**JADY**. Phase III. Rheumatoid arthritis. Since 2015. Sub Investigator  
**ABBVIE**. Phase III Kidney failure and diabetes. Since 2015. Sub Investigator  
**CTT** Phase III COPD Since Apr-2015-2017. Sub investigator  
**MK-018**. Phase III. Diabetes type II and cardiovascular risk. Since 2014-2016. Sub Investigator  
**AMGEN 0142**. Phase III. Osteoporosis.2014-2017 Sub investigator  
**MK 8835-001**. Phase III .Diabetes Since 2015 to 2017. Sub Investigator  
**MK 8835-005**. Phase III. Diabetes. Since 2015 to 2017. Sub Investigator  
**THEMIS**. Fase III.Diabetes with cardiovascular risk. Since 2015. Sub Investigator  
**GEMINI**. Phase III. Cardiovascular event 2016-2017. Sub investigator  
**TERRANOVA**. Phase III. COPD. Since 2015 Sub Investigator.  
**MARINER** Phase III. Risk of venous thromboembolism at discharge. Since 2015. Sub investigator

**CV185316 AUGUSTUS**. Phase IV. Atrial fibrillation and acute coronary syndrome. Since 2016. Sub investigator  
**OLYMPUS**. Phase III. Chronic Renal Failure with Anemia. Since 2016 Sub investigator  
**CREPENCE**. Phase III. Chronic Renal Failure with diabetes Since 2016 Sub investigator  
**VOYAGER**. Phase III. Risk of thrombotic vascular events. Since 2016 Sub investigator  
**GA 28949**. Phase III. Moderate to severe ulcerative colitis Since 2017. Sub investigator  
**GA 28951**. Phase II/III Extensión. Moderate to severe ulcerative colitis. Since 2017 Sub investigator  
**PT010005** Phase III COPD. Since 2017. Sub Investigator.  
**PT009003 SOPHOS**. Phase III COPD. Since 2017. Sub investigator  
**MK0431-848**. Phase III DBT 2. Since 2017. Sub investigator  
**MK0431/845** Phase III. DBT 2. Since 2017. Sub investigator  
**MK8835-004-01/B1521021**. Phase III Diabetes 2 with established vascular disease Since 2017. Principal Investigator  
**ASCEND-200808** Phase III. Anemia associated with chronic kidney disease. Since 2017. Sub investigator  
**AKB-6548-CI-0015**. Phase III. Anemia associated with chronic kidney disease. Since 2017. Sub investigator  
**AKB-6548-CI-0014**. Phase III. Anemia associated with chronic kidney disease. Since 2017. Sub investigator  
**DAPA CKD- D169AC00001**. Phase III. Chronic renal disease. Since 2017. Sub investigator  
**DAPA HF D1699C00001**. Phase III. Chronic heart failure with reduced ejection fraction. 2017 Sub Investigator  
**MNK4049**. Phase III. Focal and segmental sclerosis. Since 2017 Sub investigator  
**MLN0002SC-3030** Phase IIIb ulcerative colitis Since 2017 Sub investigator  
**MLN0002SC-3031** Phase III. ulcerative colitis Since 2017 Sub investigator  
**PROMINENT**. Phase III. Cardiovascular disease, triglyceride reduction in diabetic patients. Since 2017. Sub investigator  
**ETC1002-043CLEAR OUTCOMES**. Phase III. Intolerance to statins with cardiovascular risk. Since 2017. Sub investigator  
**GA29350** Phase II Rheumatoid arthritis.. Since 2017. Sub Investigator  
**GA30067** extention Phase II Rheumatoid arthritis.. Since 2018 Sub Investigator.  
**BI1245.110**. Phase III.. Chronic heart failure with preserved ejection fraction . Since 2018. Sub investigator  
**BI 1245.121**. Phase III Chronic heart failure with reduced ejection fraction. Since 2018. Sub investigator  
**EFC14875. SCORED** Phase III Cardiovascular and renal events in patients with DBT II, cardiovascular risk factors and moderate failure. Since 2018. Sub investigator  
**EFC14837** Phase III Diabetes with moderate renal disease. Since 2018 Principal investigator  
**EFC15116** Phase III Diabetes with severe kidney disease. Since 2018 Principal Investigator  
**CREDO 2 / CLO4041023**. Phase III Rheumatoid arthritis. Since 2018. Sub Investigator  
**CREDO 3 / CLO4041025**. Phase III Rheumatoid arthritis. Since 2018 Sub Investigator  
**205270** Phase III Anemia associated with chronic kidney disease. Since 2018. Sub Investigator  
**HZA107116**. Phase III Astma in children 5 to 17 years old. Since 2018 Sub investigator  
**204837** Phase III. Dialysis patients with anemia related to chronic kidney disease. Since 2018. Sub Investigator  
**CREDO 4/CLO041024**. Phase III Rheumatoid arthritis Since 2019 Sub investigator  
**OBS15459** Phase IV Diabetes. Observational Study. Since 2019. Sub investigator  
**RLM-MD-02** Phase III diabetic gastroparesis. Since 2009 Principal investigator  
**RLM-MD-03** Extensión Phase III diabetic gastroparesis. Since 2009 Principal investigator  
**RLM-MD-04** Phase III diabetic gastroparesis. Since 2009 Principal investigator  
**DELIVER** Phase III Chronic heart failure with preserved ejection fraction . Since 2019 Sub Investigator  
**BOREAS** Fase III. EPOC. Desde 2020. Sub Investigador  
**CONTRAST 1 201790-** Phase III Artritis reumatoidea. Desde 2020 Sub Investigador  
**CONTRAST 2 202018-** Phase III Artritis reumatoidea. Desde 2020 Sub Investigador  
**TRICIDA**, Fase IIIb Acidosis Metabólica. Desde 2019 Sub Principal  
**PLATFORM PACRD2001-** Phase II Crohn's Disease Sub Investigator Since 2020  
**QUASAR CNT01959UCO3001** Phase IIb/III Ulcerative colitis. Sub Investigator Since 2020  
**NODE 303**. Phase III. Paroxysmal Supraventricular tachycardia. Sub Investigator. Since 2020  
**MIT-Do001-C301(Estetra)** Phase III. Post menopausal woman with vasomotor symptoms. Sub Investigator. Since 2020  
**READY I (Cusa)** Phase III. Use of Cusa-081 for dysfunction of central venous access devices (DAVC) Principal Investigator. Since 2020  
**CONTRAST X** Phase III Rheumatoid arthritis Sub Investigator. Since 2020  
**MATINEE** Phase IIIA. Epoc with eosinophilic levels. Since 2021. Sub Investigator  
**AMETHYST** Phase II. Heart failure with preserved EF. Since 2021. Sub Investigator Investigator  
**AMEERA-5** Phase III. Breast cancer Since 2021. Sub Investigator  
**213400** Phase III Non-small cell lung cancer. Since 2021 Sub Investigator  
**ARENA APD334-202** Phase III. Crohn's disease. Since 2021 Sub Investigator  
**MEDI3506** Phase IIb. Diabetic nephropathy. Since 2021 Principal Investigator  
**1366,0002** Phase III Non-diabetic kidney disease. Since 2021 Sub Investigator  
**1366,0005** Phase III Diabetic chronic kidney disease. Since 2021 Sub Investigator  
**CC-93538-EE-01** Phase III Eosinophilic esophagitis. Since 2021 Sub Investigator  
**ANJ900D3501** Phase III Diabetes with variable renal function. Since 2021. Sub Investigator  
**D7551C00001** Phase IIb. Chronic proteinuric kidney disease. Since 2021 Sub Investigator

DIALIZE Phase III Arrhythmia in patients on chronic hemodialysis due to recurrent hyperkalemia. Since 2021 Sub Investigator  
 GKPTN Platform Study. Since 2021 Sub Investigator  
 INS1007-301 ASPEN Stage III Bronchiectasis. Since 2021 Sub Investigator  
 TACKLE Phase III Treatment of Covid in non-hospitalized adult patients. Since 2021 Principal Investigator  
 KANGTAI Phase III Covid-19 Vaccine Since 2021 Sub-Investigator  
 BANNER Phase IIIA HIV Since 2021 Sub Investigator  
 RPC01-3201 Moderate to severe Crohn's disease From 2022 Sub Investigator  
 ZEUS Phase III Cardiovascular disease, chronic renal failure. Since 2022 Sub Investigator  
 ALIGN Phase III IgA nephropathy and progressive loss of renal function. Sub Investigator  
 STABILIZE Phase III Chronic kidney disease and hyperkalaemia From 2022. Principal Investigator  
 D4325C00001 ZENIT Phase IIB CKD with glomerular filtration rate between 20 and 60 ml/min/1.73 m2 Sub Investigator  
 PILASTER Phase III Epop and chronic bronchitis. Since 2021. Sub Investigator  
 GB4311 Phase IIB COPD. Since 2022 Sub-Investigator.  
 GO42784 LIDERA Phase III Breast cancer. Since 2022 Sub-Investigator  
 BI 1378-0005 Chronic kidney disease. Since 2022. Sub-Investigator  
 23OLE304 TOPAZ Phase III Lupus. Since 2022 Sub-Investigator  
 WILLOW Phase II Lupus erythematosus. Since 2022. Sub-Investigator  
 K-001-201 Phase II NASH with liver fibrosis Since 2022 Sub Investigator  
 JASMINE 80202135SLE2001 Systemic Lupus Erythematosus (SLE). Since 2023. Sub-Investigator  
 SURMOUNT I8F-MC-GPIJ Phase III Obesity. Since 2023. Sub-Investigator  
 RPC01-3204 Moderate to severe Crohn's disease. Since 2022 Sub-Investigator  
 RPC01-3203 Moderate to severe Crohn's disease. Since 2022 Sub-Investigator  
 CC-93538-EE-02 (Extension) Phase III Eosinophilic esophagitis. Since 2022 Sub-Investigator  
 BI 1378-0005 Kidney Disease. Since 2022. Sub Investigator  
 JASMINE 80202135SLE2001 Systemic Lupus Erythematosus (SLE) Since 2023. Sub Investigator  
 MS200569\_0048 WILLOW LTE Phase II Lupus erythematosus Since 2023. Sub-investigator  
 J2A-MC-GZGU Phase III Adults with Type 2 diabetes and inadequate glycemic control with Metformin. Since 2023 Sub Investigator  
 23OLE301 (AMETHYST) Phase II Cutaneous lupus erythematosus. Since 2023 Sub Investigator  
 EX6018-4915 HERMES Phase III Patients with heart failure and inflammation. Since 2023 Sub Investigator  
 70033093AFL3002 LIBREXIA AFL Phase III Patients with Atrial Fibrillation Dede 2023 Sub Investigator  
 70033093ACS3003 LIBREXIA ACS Phase III Acute coronary syndrome. Since 2023 Principal Investigator  
 CR845-310302 KICK 2 Phase III ITCH OF MODERATE INTENSITY A SEVERE IN SUBJECTS WITH CHRONIC KIDNEY DISEASE. Since 2023 Sub Investigator  
 ACTIV-2b SCORPIO-HR Phase III Non-hospitalized patients with COVID-19 Since 2023 Principal investigator  
 AT-03A-017 Phase III High-risk outpatients with COVID-19. Since 2023 Principal Investigator  
 209978 MARS-17 Phase II Osteoarthritis of the knee. Since 2023 Sub Investigator  
 AMG592 20170104 Phase II Moderate to severe ulcerative colitis. Since 2022 Sub Investigator  
 AMG592 20210210 EXT Phase II Moderate to severe ulcerative colitis. Since 2022 Sub Investigator  
 CNT01959UCA3004 ASTRO Phase III Moderately to severely active ulcerative colitis. Since 2023 Sub Investigator  
 K-001-201 Phase II NASH with liver fibrosis Since 2022 Sub Investigator  
 BUS-P3-01 CALM Bellus Phase III Refractory chronic cough. Since 2023 Sub Investigator  
 EDP 938-104 ENANTA Phase IIB Acute syncytial respiratory virus. Since 2023 Sub Investigator GB43374 OLE COPD Since 2023 Sub Investigator  
 CLI-06001AA1-04 PILASTER Phase III COPD Since 2023 Sub Investigator  
 CLI-06001AA1-05 PILLAR Phase III COPD Since 2023 Sub Investigator  
 CLI-05993AA-06 TRITON Phase III COPD Since 2023 Sub Investigator  
 1368-0098 Phase IIB/III. Hidradenitis suppurativa. Since 2023 Sub Investigator  
 INCB 18424-319 Phase III Prurigo nodularis. Since 2023 Sub Investigator  
 77242113PSO3001 Phase III Moderate to severe plaque psoriasis. Since 2023 Sub Investigator  
 1366-0031 Phase II Cutaneous sclerosis. Since 2023 Sub Investigator  
 D6970C00002 BaxHTN Phase III Participants with Hypertension Uncontrolled with Two or More Medications including Participants with Resistant Hypertension Since 2024 Sub Investigator  
 MK 7240-001 CU Phase III participants with moderately to severely active ulcerative colitis Since 2024 Sub Investigator  
 219700 VOLITION Phase IIIb HIV-1 in antiretroviral therapy-naïve adults Sub Investigator Since 2024  
 23OLE306 (EMERALD) Phase III Systemic lupus erythematosus. Since 2024 Sub Investigator  
 D4325C00007 Chronic kidney disease and proteinuria. Since 2024 Principal Investigator  
 D7830C00004 FORTUNA Phase IIB. Non-alcoholic non-cirrhotic steatohepatitis with fibrosis (NASH) Since 2024 Principal Investigator  
 D4325C00010 ZENITH Phase III Chronic kidney disease and high proteinuria. Since 2024 Principal Investigator  
 MRXC-302 Phase III Moderate disease or severe diabetic foot infections. Since 2024 Sub Investigator  
 ACT17746 LIBERTY Phase II Ulcerative colitis with eosinophilic profile. Since 2024 Sub Investigator  
 78934804UCO2001 (DUET-UC) Phase IIB Moderately to severely active ulcerative colitis. Since 2024 Sub Investigator

15 JAN 2024

Dr. Alejandro J. Pereyra  
 Esp. en Clínica Médica  
 M.P. 93 608